WisemanG.A., KornmehlE., LeighB., ErwinW.D., PodoloffD.A., SpiesS., SparksR.B., StabinM.G., WitzigT., WhiteC.A.: Radiation dosimetry results and safety correlations from 90-Yibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med, 44: 465–474, 2003.
2.
DaviesA.J.: Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I (131) tositumomab. Oncogene, 26: 3614–3628, 2007.
3.
MorschhauserF., IllidgeT., HugloD., MartinelliG., PaganelliG., ZinzaniP.L., RuleS., LiberatiA.M., MilpiedN., HessG., SteinH., KalmusJ., MarcusR.: Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood, 110: 54–58, 2007.
4.
WitzigT.E., MolinaA., GordonL.I., EmmanouilidesC., SchilderR.J., FlinnI.W., DarifM., MacklisR., VoK., WisemanG.A.: Long-term responses in patients with recurring or refractory B-cell non- Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer, 109: 1804–1810, 2007.
5.
MartelliM., GuglielmiC., ColuzziS., AvvisatiG., AmadoriS., GiovanniniM., TorromeoC., MandelliF.: P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol, 11: 2362–2369, 1993.
